LabViews Newsletter October 2008
Nov. 10 - 11, 2008
InterContinental Wien
Vienna, Austria
Dec. 4 - 5, 2008
Hotel Hilton
Barcelona, Spain
Jan. 12 - 12, 2009
Sheraton Premiere
Vienna, VA
Jan. 26 - 28, 2009
Red Rock Resort
Las Vegas, NV
Jan. 26 - 28, 2009
Westin San Diego
San Diego, CA
Feb. 26 - 27, 2009
Washington, DC
Contact Us
Click
Click
Click
ADVERTISMENT
i3
i3 is one of the world’s leading providers of specialized pharmaceutical services, delivering integrated scientific strategies and solutions throughout the product lifecycle. At any point from development to market, anywhere you need to be, we deliver specialization and scientific depth for your most intricate challenges. Look to us to see all the possibilities.
Learn how Cardiac Safety strategies can protect drug research program. Web-Seminar: “Leveraging a Multiphase QT Strategy to Expedite Development and Reduce Investment Risk” on Wednesday, November 5th, 2008, from 11:00am - 12:30pm EST.
For 25 years, IBT Laboratories has provided the broadest range of allergy and immunological tests available from a single provider to complement pharmaceutical product development.
EXPeRT® ePRO – Simplified. Delivered. Guaranteed. Trust your patient reported outcomes with eRT, an industry-leading clinical technology provider.
You are subscribed to apct_enews_labviews as
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025